Skip directly to content

Safety Information inderal

PrINDERAL®-LA (Propranolol Hydrochloride)

Indications and Clinical Use:

Maintenance therapy in the treatment of hypertension and for the prophylaxis of angina pectoris. Not indicated for the emergency treatment of hypertensive crises.

Can be used in combination with thiazide-like diuretics and/or peripheral vasodilators.
Initial treatment and individual titration of dosage must always be carried out with conventional tablets before use of long-acting formulation.
Not recommended for use in children.


  • History of or current reports of bronchial asthma or bronchospasm
  • Allergic rhinitis during the pollen season
  • Sinus bradycardia and greater than first degree block
  • Cardiogenic shock
  • Right ventricular failure secondary to pulmonary hypertension
  • Congestive heart failure unless the failure is secondary to a tachyarrhythmia treatable with propranolol hydrochloride;
  • Patients prone to hypoglycaemia
  • Bradycardia
  • Hypotension
  • Metabolic acidosis
  • Severe peripheral arterial circulatory disturbance
  • Sick sinus syndrome
  • Untreated phaeochromocytoma
  • Uncontrolled heart failure
  • Prinzmetal’s angina

Relevant warnings and precautions:

  • Risk of fall in blood pressure when used with a thiazide-like diuretic and/or peripheral vasodilator
  • Depressing atrioventricular conduction when used with digitalis
  • Risk of cardiac failure
  • Wolff- Parkinson-White Syndrome
  • Reduction of cardiac output in cases of arrhythmia
  • Abrupt discontinuation (angina pectoris or ischaemic heart disease, and peri-operative)
  • May mask the clinical signs of hyperthyroidism or its complications
  • Cutaneous reactions
  • Risk of oculomucocutaneous syndrome
  • Anaphylactic/anaphylactoid reactions associated with the administration of propranolol hydrochloride (use epinephrine with caution)
  • Patients with renal or hepatic impairment
  • Patients who are pregnant or breastfeeding
  • Monitor and test for liver and renal functions at regular intervals during long-term treatment with Inderal-LA.

For more information:

Please consult the product monograph by clicking here for important information relating to adverse reactions, drug interactions, and dosing information which have not been discussed in this piece.

The product monograph is also available by calling 1-800-463-6001.

INDERAL®-LA, AstraZeneca UK Limited, owner/Pfizer Canada Inc., Licensee